

List of Publications by Citations

Source: <https://exaly.com/author-pdf/322347/lee-s-simon-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53 papers	3,932 citations	16 h-index	62 g-index
64 ext. papers	4,310 ext. citations	4 avg, IF	4.54 L-index

#	Paper	IF	Citations
53	Cyclooxygenase in biology and disease. <i>FASEB Journal</i> , 1998 , 12, 1063-1073	0.9	1948
52	Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 745-53	5.7	508
51	Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1591-602		410
50	Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. <i>Arthritis and Rheumatism</i> , 2000 , 43, 4-13		237
49	Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. <i>Pain</i> , 2009 , 143, 238-245	8.25	149
48	Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence?. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1192-203		147
47	Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 819-25		106
46	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019 , 46, 1021-1027	4.1	47
45	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019 , 46, 1028-1035	4.1	33
44	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019 , 46, 1014-1020	4.1	30
43	NSAIDs and the elderly. Toxicity and economic implications. <i>Drugs and Aging</i> , 1997 , 10, 119-30	4.7	30
42	Osteoporosis. <i>Clinics in Geriatric Medicine</i> , 2005 , 21, 603-29, viii	3.8	25
41	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017 , 44, 1515-1521	4.1	24
40	Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. <i>Journal of Rheumatology</i> , 2016 , 43, 182-6	4.1	21
39	A first step to assess harm and benefit in clinical trials in one scale. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 627-32	5.7	21
38	Osteoporosis. <i>Rheumatic Disease Clinics of North America</i> , 2007 , 33, 149-76	2.4	16
37	Osteoarthritis. <i>Current Rheumatology Reports</i> , 1999 , 1, 45-7	4.9	16

36	Preliminary development of a responder index for chronic low back pain. <i>Journal of Rheumatology</i> , 2007 , 34, 1386-91	4.1	16
35	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. <i>Journal of Rheumatology</i> , 2015 , 42, 1947-1953	4.1	15
34	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. <i>Journal of Rheumatology</i> , 2017 , 44, 1551-1559	4.1	15
33	Changes in serum levels of type I and III procollagen extension peptides during infusion of human parathyroid hormone fragment (1-34). <i>Journal of Bone and Mineral Research</i> , 1988 , 3, 241-6	6.3	15
32	A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. <i>Journal of Rheumatology</i> , 2017 , 44, 1754-1758	4.1	11
31	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017 , 44, 1916-1919	4.1	10
30	The treatment of rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004 , 18, 507-38	5.3	10
29	Dialogue on Developing Consensus on Measurement and Presentation of Patient-important Outcomes, Using Pain Outcomes as an Exemplar, in Systematic Reviews: A Preconference Meeting at OMERACT 12. <i>Journal of Rheumatology</i> , 2015 , 42, 1931-1933	4.1	8
28	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. <i>Journal of Rheumatology</i> , 2015 , 42, 1934-1942	4.1	6
27	Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group. <i>Journal of Rheumatology</i> , 2019 , 46, 1179-1182	4.1	5
26	How to ascertain drug safety in the context of benefit. Controversies and concerns. <i>Journal of Rheumatology</i> , 2009 , 36, 2114-21	4.1	5
25	Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. <i>Journal of Rheumatology</i> , 2019 , 46, 1168-1172	4.1	4
24	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. <i>Journal of Rheumatology</i> , 2020 , 47, 1379-1384	4.1	4
23	Observations from the OMERACT Drug Safety Summit, May 2008. <i>Journal of Rheumatology</i> , 2009 , 36, 2110-3	4.1	4
22	The COX 2 selective inhibitors: what the newspapers have not told you. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007 , 65, 229-41		4
21	Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group. <i>Journal of Rheumatology</i> , 2019 , 46, 1360-1364	4.1	3
20	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 1053-1058	4.1	3
19	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 1173-1178	4.1	3

18	OR-25: Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: Results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , 2003 , 16, A11	2.3	3
17	A world without Vioxx: to COX-2 or not to COX-2?. <i>Cleveland Clinic Journal of Medicine</i> , 2004 , 71, 849-50, 852, 854 passim	2.8	3
16	Do topical NSAIDs work?. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 458-9		2
15	Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets. <i>Drug Information Journal</i> , 2006 , 40, 111-116		2
14	Perception of risk: the state of COX-2 selective inhibitors. <i>Current Rheumatology Reports</i> , 2005 , 7, 163-6	4.9	2
13	Postmenopausal Osteoporosis	183-242	2
12	A Food and Drug Administration primer. <i>Arthritis and Rheumatism</i> , 2006 , 55, 4-8		1
11	Knowledge Translation for Patients: Methods to Support Patients' Participation in Decision making about Preference-Sensitive Treatment Options in Rheumatology	41-62	1
10	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1139-1145	5.3	1
9	The COX-2 inhibitors: a reasoned review of the data. <i>Swiss Medical Weekly</i> , 2005 , 135, 419-24	3.1	1
8	Frequency of COX2-inhibitor use in the clinic prior to market withdrawals. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 16-7		0
7	Is milnacipran effective in treating pain in patients with fibromyalgia?. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 126-7		
6	OMERACT 2020: A virtual (R)evolution. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 588-592	5.3	
5	Shoulder and Elbow Pain	315-392	
4	Spondyloarthropathies	393-442	
3	Systemic Sclerosis	443-493	
2	Primary Systemic Vasculitis	495-527	
1	OMERACT: An Ongoing Evidence-Based Initiative to Improve the Quality of Outcome Measures in Rheumatology	19-24	

